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The Journal of Infectious Diseases
MAJOR ARTICLE
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Background. Ebola virus (EBOV) is a highly lethal member of the Filoviridae family associated with human hemorrhagic
disease. Despite being a sporadic disease, it caused a large outbreak in 2014–2016 in West Africa and another outbreak recently in
the Democratic Republic of Congo. Several vaccine candidates are currently in preclinical and clinical studies but none are stable
without cold chain storage.
Methods. We used preservation by vaporization (PBV), a novel processing technology to heat-stabilize FiloRab1 (inactivated
rabies-based Ebola vaccine), a candidate Ebola vaccine, and stored the vials at temperatures ranging from 4°C to 50°C for 10 days to
12 months. We immunized Syrian hamsters with the best long-term stable FiloRab1 PBV vaccines and challenged them with rabies
virus (RABV).
Results. Syrian hamsters immunized with FiloRab1 PBV–processed vaccines stored at temperatures of 4°C and 37°C for
6 months, and at 50°C for 2 weeks, seroconverted against both RABV-G and EBOV-GP. Notably, all of the FiloRab1 PBV vaccines
proved to be 100% effective in a RABV challenge model.
Conclusions. We successfully demonstrated that the FiloRab1 PBV vaccines are stable and efficacious for up to 6 months when
stored at temperatures ranging from 4°C to 37°C and for up to 2 weeks at 50°C.
Keywords. Ebola; rabies; vaccine; preservation by vaporization; stable; protection; challenge model.
The 2014–2016 Ebola virus (EBOV) outbreak in West Africa
ended with >28 600 cases and 11 325 deaths [1]. More recently,
an EBOV outbreak began in August 2018 in the Democratic
Republic of Congo and, as of 5 March 2019, has resulted in
841 confirmed cases and 503 confirmed deaths [2]. These are
just the 2 most recent EBOV outbreaks documented since
the 1970s, all which indicate the need for an efficient vaccine
against EBOV that can easily be stockpiled and distributed to
communities at risk.
Several vaccine candidates are currently in preclinical and
clinical studies [3], with the most advanced being a live attenuated recombinant vesicular stomatitis virus (rVSV) expressing the Ebola virus glycoprotein (rVSV-ZEBOV) instead
of the VSV glycoprotein (G). The experimental rVSV-ZEBOV
vaccine was developed to protect against Ebola virus disease
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and found to be highly efficacious when used in a ring vaccination clinical trial in the communities of Conakry, Guinea
and in Sierra Leone [4–6]. The live attenuated rVSV-ZEBOV
candidate vaccine was granted “breakthrough therapy designation” status by the US Food and Drug Administration and
“priority medicine” status by the European Medicines Agency
[7]. However, its efficacy was recently challenged by reports that
the vaccine group received better medical care than the control
group [8, 9]. Independent of its potential efficacy, the vaccine
utilization drawback is that it requires –70°C storage. Such a
requirement represents a significant logistical challenge, especially in outbreak countries with inadequate cold chain capacity.
Furthermore, the rVSV virus may be affected by pH, temperature, and protein concentration [10]. The vaccine can suffer
loss in potency due accidental heating or freezing, with studies
showing that the stability of the rVSV-ZEBOV vaccine is limited to 24 hours at 25°C and to 1 week at 4°C, and storage at
40°C caused a significant reduction in the vaccine titer [11].
Lyophilized rabies vaccine has been shown to be the most
temperature- and heat-stable of all vaccines in that it remains effective when stored for 24–48 months at 4°C [12].
However, maintaining a constant temperature of 4°C requires
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Inactivated Rabies Virus–Based Ebola Vaccine Preserved
by Vaporization Is Heat-Stable and Immunogenic Against
Ebola and Protects Against Rabies Challenge

METHODS
Generation of FiloRab1 Vaccine

The vaccine vector BNSP333-coZGP (FiloRab1) was constructed, recovered, purified with sucrose, inactivated with
β-propiolactone (BPL), and characterized as previously described [16–18, 20]. The vaccine was stored at –80°C.
1522 • jid 2019:220 (1 November) • Kurup et al

Preservation by Vaporization of FiloRab1

Liquid, BPL-inactivated FiloRab1 (1 mg/mL) vaccine was
mixed with 4 parts preservation solution comprised of 20%
(w/w) sucrose, 10% α-methlyglucoside, 1% monosodium glutamate, and 0.3% sodium hexametaphosphate in deionized water,
pH 7. This vaccine preservation solution mixture was distributed by 250-µL portions into 3-mL borosilicate glass serum
vials. Vials were dried using the PBV foam drying process in a
conventional Virtis Genesis freeze dryer. After 2 hours of primary drying, the material formed a solid dry foam that was
stable under vacuum. Subsequent desorption drying was performed under vacuum with stepwise temperature raises from
25°C to 45°C. Desorption drying at 45°C continued for 24
hours to ensure stability of the vaccine at ambient temperatures.
The vials were sealed under vacuum and crimped with aluminum seals. Samples were stored with Drierite in incubators
for stability storage under refrigeration (4°C ± 3°C), room temperature (22°C ± 3°C), 37°C, and 50°C. Samples were retrieved
from storage temperatures at specific time points of 10 days, 2
weeks, 1 month, 3 months, 6 months, and 12 months, and tested
for antigenicity as compared to liquid control vaccine that was
stored at –80°C. Each PBV vial contained 0.087 mL (87 μg) of
the original FiloRab1 –80°C vaccine (1 mg/mL).
Antigenicity ELISA

Vials of FiloRab1 PBV vaccines were resuspended in 500 μL of
cell culture–grade water (HyClone Water, Cell Culture Grade
[Endotoxin-Free]) and incubated at room temperature for 10
minutes, shaking gently. Resuspended vaccines were subsequently stored at 4°C or on ice during experiments. FiloRab1
PBV Vaccine and the FiloRab1 –80°C stocks were diluted in 1×
carbonate coating buffer, at a starting concentration of 0.02 mg/
mL (Pierce BCA assay) and further serially diluted 3-fold
within the 96-well plates (Nunc, Immulon 4 HBX), with 100-μL
final volume per well. Plates were washed (1× PBST = 1× PBSTween20; 1× phosphate buffered saline, 0.05% Tween-20),
blocked (5% milk in 1× PBST), and washed (1× PBST) before
being probed with either 1C5 anti-RABV-G (Abcam) or 15H10
anti-EBOV-GP (Hybridoma, BEI resources, NR-12184) mouse
antibodies at 2 mg/mL or 4 mg/mL, respectively. Goat antimouse immunoglobulin G (IgG) (Heavy and Light chain [H+L])
horseradish peroxidase (HRP) (Jackson Immunoresearch, code
115-035-146, 0.8 mg/mL, 1:10 000) secondary antibody was
used to detect RABV-G and EBOV-GP content. The later steps
of the ELISA were done as previously described [16].
Animals Ethics Statement

Animal use protocols were approved by the Centers for Disease
Control and Prevention’s Institutional Animal Care and Use
Committee under protocol 2694WUHAMC. In brief, 6-weekold, female Syrian hamsters (strain Hsd:Han Aura, Envigo) were
assigned to groups of 12 animals. Animals were induced and
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a refrigeration structure, and methods need to be implemented
that are very expensive and difficult to manage in emerging
countries and/or rural areas.
Preservation by vaporization (PBV) is a novel technology
that can reduce the need for such methodical refrigeration. It is
a cost-effective and efficient industrial scale stabilization of proteins, viruses, bacteria, and other sensitive biologicals (US patent
number 9469835) [13]. Smith et al reported that live attenuated rabies virus (ERAg333) was successfully formulated into a stable, dry
foam using the PBV processing technology. The vaccine remained
stable for 23 months at 22°C, 2 months at 37°C, and 3 hours at
80°C. More importantly, both the inactivated RABV PBV (inactivated by irradiation) and the live RABV PBV vaccines effectively
induced rabies virus neutralizing antibody (VNA) titers similar to
the commercial rabies vaccine in vaccinated animals and protected
all mice from an intramuscular (IM) RABV challenge [14, 15].
This data indicated that PBV processing could possibly render
similar potency to the inactivated rabies-based Ebola vaccine
(FiloRab1), a candidate Ebola vaccine that has proven efficacious
in several nonhuman primate (NHP) studies [16–18]. FiloRab1
consists of the recombinant RABV that expresses the rabies glycoprotein (RABV-G) and the Ebola glycoprotein (EBOV-GP)
on its virion surface. The efficacy of this vaccine was enhanced
to 100% protection when adjuvanted with glucopyranosyl lipid
A in stable emulsion (GLA-SE) in NHP studies [18], providing
protection against both RABV and EBOV.
In this study, we present data on the PBV process that was
used to generate the FiloRab1 PBV vaccines prior to storage at
4°C, 25°C, 37°C, and 50°C for 10 days to 12 months. We assessed the antigenic stability of RABV-G and EBOV-GP on the
virion of FiloRab1 PBV vaccines by antigen-specific enzymelinked immunosorbent assay (ELISA). The best long-term
stable FiloRab1 PBV candidates were tested for immunogenicity in a Syrian hamster model. As Ebola challenge requires
a Biosafety Level 4 (BSL-4) facility and appropriate small animal models are not available, we chose to test the efficacy of our
FiloRab1 PBV vaccines using a well-established Syrian hamster
model for RABV [19]. Here we report the immunogenicity of
the FiloRab1 PBV vaccines stored at 4°C and 37°C for 6 months
and at 50°C for 2 weeks, against both RABV-G and EBOV-GP.
Notably, all of the FiloRab1 PBV vaccines were 100% efficacious
in a RABV challenge model. Thereby, we successfully demonstrated that the FiloRab1 PBV vaccines are stable and efficacious for up to 6 months when stored at temperatures ranging
from 4°C to 37°C and for up to 2 weeks at 50°C.

maintained under anesthesia with 1%–5% inhalation isoflurane
and were monitored postprocedure until fully recovered.
Animal Study

Direct Fluorescent Antibody Test

The brain stems collected at necropsy were tested for rabies diagnosis by the direct fluorescent antibody (DFA) test [21].

RESULTS
Heat Stabilization of FiloRab1

To stabilize the FiloRab1 vaccine, we used the PBV stabilization
process. We then stored the samples at 4°C, 25°C, 37°C, and
50°C. Samples were removed after 10 days, 2 weeks, and 1, 3, 6,
and 12 months, stored at 4°C, and analyzed accordingly. Liquid
samples from the initial inactivated vaccines stocks were stored
at –80°C as standards.
Antigen Stability of FiloRab1 Vaccine by ELISA

After storage at the different temperatures, the content of the 2 viral
glycoproteins, RABV-G and EBOV-GP, on the surface of FiloRab1
virions (inactivated vaccine) were determined by EBOV-GP– and
RABV-G–specific ELISAs. We found that the EBOV-GP and
RABV-G content of FiloRab1 PBV vaccines stored at 4°C, 25°C,
and 37°C were not affected when stored for 10 days to 12 months
in comparison to the FiloRab1 vaccine stored at –80°C (Figure 1).
The FiloRab1 PBV sample kept at 50°C showed no effect on the
EBOV-GP and the RABV-G contents for up to 2 weeks, but small
decreases in antibody binding to both the RABV-G and EBOV-GP
were seen for FiloRab1 PBV 50°C samples at the 1-month time
period. Therefore, only the lower temperatures of 25°C and 37°C
were studied for the whole period of 12 months. The results of
these experiments indicated that the PBV process is an excellent
method to heat-stabilize the FiloRab1 vaccine with respect to the
conservation of antigens within the virions.
Immunogenicity of Antigenically Stable Vaccines in Syrian Hamsters

Rapid Fluorescent-Focus Inhibition Test

Serum separated from collected blood was used to determine
the titer of rabies virus neutralizing antibody by the rapid
fluorescent-focus inhibition test (RFFIT) [22].
Analysis of Humoral Responses by ELISA

Individual Syrian hamster sera and control sera were tested for the
presence of EBOV-GP IgG by ELISA, as previously described [16].
Goat anti-Syrian hamster IgG (H+L) HRP (Jackson Immunoresearch,
code 107-035-142, 0.8 mg/mL, 1:20 000) secondary antibody was
used for detection of EBOV-GP–specific responses in sera.
Statistical Analysis

All statistical analysis was performed by using GraphPad Prism
7 software. For the antigenicity ELISA, log half maximal effective concentration (EC50) for samples within each incubation
period (10 days to 12 months) was normalized and compared to

While the ELISA was used for the initial screening of the stability of the vaccine, we wanted to analyze whether FiloRab1
PBV vaccine was still immunogenic when stored at different
temperatures. For this study, we chose the samples of FiloRab1
PBV stored at 4°C or 37°C for 6 months and FiloRab1 PBV
stored at 50°C for 2 weeks (Figure 2A). The liquid FiloRab1
vaccine stored at –80°C served as the positive control since previous experiments in NHPs and mice indicated that the liquid
formulation stored at –80°C is stable for several years [16]. We
utilized the Syrian hamster model, which is the most consistent
animal system for RABV virus challenge experiments.
RABV Neutralizing Antibodies Induced by FiloRab1 and Its Stabilized
Derivates

The rabies-specific potencies of the FiloRab1 PBV vaccines and the FiloRab1 –80°C vaccines were analyzed by
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Microchip identifiers (Bio Medic Data Systems, Seaford, Delaware)
were implanted subcutaneously in the animals’ backs. The PBV
vaccines were reconstituted in 0.5 mL of sterile water. All animals were vaccinated IM with 0.05 mL of the vaccine in the hind
limb according to the group, on day 0 and boosted with the same
vaccine dose at day 28. Three control groups of 12 Syrian hamsters each received either 1/20th dose of the human rabies vaccine
RabAvert (group 1) or a high dose of the liquid FiloRab1 vaccine
of 50 μg (group 2); or they were not vaccinated to serve as a control group for the RABV challenge (group 6). The experimental
groups of 12 Syrian hamsters each were immunized with 8.7 μg
of the FiloRab1 PBV vaccines stored at 4°C for 6 months (group
3), 37°C for 6 months (group 4), or 50°C for 2 weeks (group 5).
Blood was collected on days 0, 14, 28, and 56 using the subclavicle
method: 0.2 mL of blood was collected from the vena cava using
a 25 g needle and 1-mL syringe. Four animals (one group 1 and
one group 4 on day 14; one group 2 on day 28 and one group 5
on day 56) did not recover from blood collection. On day 56, all
animals were challenged with 103.5 mice intracerebral Lethal Dose
50% (MICLD50) RABV TX coyote 323R (canine variant, Mexico)
IM in the left hind leg. For the first 6 days postinfection, animals
were monitored daily and twice daily from days 7 to 21. Animals
were euthanized by isoflurane overdose at the first specific clinical
signs of rabies, according to euthanasia criteria including a pain
score, or as deemed necessary by the responsible veterinarian. All
surviving animals were euthanized on day 45 postinfection and
terminal sera were collected. A cross-section of the brain stem was
collected at necropsy.

–80°C using the Kruskal–Wallis multiple comparisons test. For
the RFFIT assays and the immunogenicity ELISA, one-way analysis of variance test was performed on log-transformed data (for
RFFIT, IU/mL; for ELISA, EC50) and a post hoc analysis using
Tukey honest significant difference test with a 95% confidence
interval to test significance within groups. The Kaplan–Meier
survival curves postchallenge were compared by performing the
log-rank (Mantel–Cox) test.
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Figure 1. Long-term antigenic stability of inactivated rabies-based Ebola (FiloRab1) preservation by vaporization (PBV) vaccines at different temperatures. Analysis of
antigenic stability of FiloRab1 PBV vaccines stored at temperatures 4°C, 25°C, 37°C, and 50°C in comparison to FiloRab1 –80°C vaccine over time periods of 10 days to
12 months by enzyme-linked immunosorbent assay. The rabies virus glycoprotein (RABV-G) and Ebola virus glycoprotein (EBOV-GP) contents for the FiloRab1 PBV 4°C, 25°C,
and 37°C vaccines were similar to FiloRab1 –80°C vaccine for the period of 10 day to 12 months. FiloRab1 PBV 50°C vaccine had similar RABV-G and EBOV-GP content to the
FiloRab1 –80°C vaccine for 2 weeks but showed slight degradation for both glycoproteins after 1 month. EBOV-GP content for all of the FiloRab1 PBV groups as measured
by the antibody 15H10 anti–EBOV-GP and presented as normalized half maximal effective concentration (EC50) to that of the FiloRab1 –80°C EBOV-GP content (%) (A) and
RABV-G content for all of the FiloRab1 PBV groups as measured by the antibody 1C5 anti–RABV-G and presented as normalized half maximal effective concentration (EC50) to
that of the FiloRab1 –80°C RABV-G content (%) (B). All statistical analysis was performed on normalized data using the Kruskal–Wallis multiple comparisons test. *P =
.01–.05; **P = .001–.01; ***P = .0001–.001 ; ****P < .0001; ns, not significant.

testing immunized Syrian hamster sera for VNAs by the
RFFIT assay (Figure 2B and Supplementary Table 1). For the
FiloRab1 –80°C–vaccinated animals, we detected neutralizing
titers ranging from 3.8 IU/mL to 46.7 IU/mL by day 56. Similar
VNA titers were detected for the 2 groups (4°C and 37°C) receiving FiloRab1 PBV vaccines. At day 56, the VNA FiloRab1
PBV 4°C group ranged from 1.8 I.U/mL to 11.2 IU/mL, and
the FiloRab1 PBV 37°C group had VNA titers from 1.7 IU/mL
to 41 IU/mL. Of note, even the FiloRab1 PBV (group 5) stored
at 50°C for 2 weeks was able to induce potential protective
immune responses >0.5 IU/mL with a range of 1.6 IU/mL to
10.4 IU/mL (except for 1 animal with a titer of 0.06 IU/mL).
The human rabies vaccine RabAvert (positive vaccine control,
group 1) had higher VNA titers, and by day 56 these VNA titers
reached 14 IU/mL to 71 IU/mL. Most importantly, no significant differences in the RABV VNA titers were detected between
the FiloRab1 –80°C vaccine and the PBV vaccines on day 28
and day 56, indicating successful heat stabilization of FiloRab1.
The day 56 antibody titers for the RabAvert rabies control group
were significantly higher (P value range, .0112 to < .0001) than
for the FiloRab1 PBV–vaccinated animals. However, all animals
in the FiloRab1 PBV–vaccinated groups (except one animal in
PBV 50°C) achieved titers >0.5 IU/mL by day 56, a result that
is recognized by the World Health Organization (WHO) as an
adequate immune response against RABV vaccine [23].
EBOV-GP–Specific Immune Responses

Because the FiloRab1 vaccine is a dual vaccine against EBOV
and RABV, we also analyzed the EBOV-GP–specific antibody
titers by an EBOV-GP–specific ELISA. We found that all groups
of immunized hamsters had only background level of antibody
titers against EBOV-GP prior to immunization (Figure 3 and
1524 • jid 2019:220 (1 November) • Kurup et al

Supplementary Figure 1). However, as early as the first analyzed timepoint at day 14, all 4 groups developed GP-specific
IgG responses, which were not significantly different between
the groups immunized with FiloRab1 –80°C and the FiloRab1
PBV–vaccinated groups. Similar findings were made for the
serum collected on day 28 and day 56. While the antibody
titers for all 4 groups increased over time due to the additional
booster immunization, the storage temperature of the vaccines
did not affect the detected immune responses. Similar to the
RABV VNAs, the PBV-vaccinated animals mounted similar
EBOV-GP IgG titers, indicating that the heat stabilization was
successful for both of the antigens of interest.
Efficacy Test in Vaccinated Animals

There is no challenge system available for EBOV (wild type)
in Syrian hamsters and a modest predictable EBOV challenge
system with a mouse-adapted variant of EBOV. However, the
efficacy of the FiloRab1 vaccine can be analyzed for effectiveness to protect against RABV by challenging the animals
with RABV. Therefore, all animals (Syrian hamster model)
were challenged IM in the hind leg with 103.5 MICLD50 TX
coyote 323R (canine RABV variant from Mexico), a highly
pathogenic primary isolate of RABV. As shown in the
Kaplan–Meier curves in Figure 4B, all of the FiloRab1 PBV–
vaccinated animals, the –80°C FiloRab1–vaccinated animals,
and hamsters immunized with RabAvert survived the RABV
challenge, whereas the unvaccinated control animals died
by day 18 postchallenge. The survival curves for vaccination
groups were significantly different from the control group
(log-rank P < .0001). Survival curves for FiloRab1 groups
were not significantly different from the RabAvert group
(log-rank P = 1.0) (Figure 4B).
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Group 3: FiloRab1 PBV stored at 4°C for 6 months
Group 4: FiloRab1 PBV stored at 37°C for 6 months
Group 5: FiloRab1 PBV stored at 50°C for 2 weeks
Group 6: Control (no vaccination, no blood collection)
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Figure 4. Inactivated rabies-based Ebola (FiloRab1) preservation by vaporization (PBV)–vaccinated animals survive rabies challenge. The FiloRab1 PBV (4°C, 37°C, 50°C),
FiloRab1 –80°C, RabAvert (commercial rabies vaccine), and control groups of vaccinated animals were challenged with 103.5 Mice Intracerebral Lethal Dose 50% rabies virus
TX coyote 323R (canine variant, Mexico) intramuscularly in the left hind leg. Animals vaccinated with FiloRab1 PBV (4°C, 37°C, 50°C), FiloRab1 –80°C, or the RabAvert group
survived lethal rabies challenge, whereas the control group (group 6) succumbed to challenge by day 18. A, Table showing the percentage survival for all groups. NA, not
applicable. B, Kaplan–Meier survival curves post–rabies challenge. Survival curves for vaccination groups are significantly different from control group (log-rank P < .0001).
Survival curves for FiloRab1 groups are not significantly different from the RabAvert group (log-rank P = 1.0). To compare the groups, a log-rank (Mantel–Cox) test analysis
was performed.

To analyze the level of protection as well as to diagnose the
cause of death of the control animals, the presence of RABV
antigen in the brain stem of challenged animals was tested by
DFA for groups 1–6 (Supplementary Table 2). Among the 12
survivors in groups 1–4, 50% of the animals were randomly
chosen to test for the presence of RABV antigen. All of these
animals were diagnosed negative for RABV antigen, indicating
the efficient prevention of viral spread. Because of the slightly
lower VNA in the FiloRab1 PBV 50°C–vaccinated group, all 12
animals were tested for RABV antigen, and all 12 were negative.
All 12 control unvaccinated animals tested positive for the presence of RABV antigen by DFA.
DISCUSSION

Heat-stable vaccines are needed in developing countries where
it can be difficult to maintain a constant cold temperature. Heat
stabilization has been a significant challenge for several vaccines against EBOV [11, 24]. For example, the VSV-based live
vaccine against EBOV must be stored at –70°C and is highly
unstable at ambient temperature [11]. By contrast, the lyophilized rabies vaccine is stable at 4°C for 24 months [12], which is
a significant improvement from frozen storage. However, even
storage at 4°C is not always available due to breaks in the cold
chain during transport to affected areas. Therefore, an efficacious vaccine that can withstand temperature ranges from 4°C
to 50°C is needed.
The second-generation RABV-based Ebola vaccine
(FiloRab1) adjuvanted with GLA-SE has shown 100% efficacy
in an Ebola challenge in 2 different NHP studies [16, 18]. In
these studies, the unadjuvanted FiloRab1 had similar rabies
1526 • jid 2019:220 (1 November) • Kurup et al

VNA titers to the GLA-SE adjuvanted group, ranging from 4 IU/
mL to 45 IU/mL, well above the WHO-recognized threshold of
0.5 IU/mL [23]. These results clearly demonstrate that FiloRab1
adjuvanted with GLA-SE can provide protection against both
Ebola and rabies. In addition, the inactivated FiloRab1 vaccine
builds on the excellent safety profile of the inactivated RABV
vaccine that can be safely administered to pregnant women,
children, and immunocompromised individuals, unlike many
of the virally vectored EBOV vaccine candidates.
Here we used the cost-effective and efficient industrialscale PBV stabilization system to stabilize the FiloRab1 vaccine. We observed that in FiloRab1 PBV vaccines, EBOV-GP
and RABV-G are antigenic stable from 4°C to 37°C for up
to 12 months. The FiloRab1 PBV 50°C samples were stable
for 2 weeks but showed slight degradation (P = .0329) after
1–3 months (Figure 1).
The long-term stable FiloRab1 PBV vaccines (stored at 4°C or
37°C for 6 months and at 50°C for 2 weeks) were used to immunize
Syrian hamsters (Figure 2A). All FiloRab1 PBV–vaccinated animals
except the 50°C group developed RABV VNA titers similar to the
–80°C FiloRab1 control by day 56 (Figure 2B and Supplementary
Table 1). Similarly, all FiloRab1 PBV–vaccinated immunized animals seroconverted against EBOV-GP, similar to the control –80°C
FiloRab1–vaccinated animals (Figure 3 and Supplementary Figure
1). This shows that the antigenic stability analyzed by ELISA was
correlative to the immunogenicity seen in the PBV-vaccinated animals. Therefore, the PBV process successfully stabilized both the
RABV-G and the EBOV-GP on the virion surface.
We next tested the efficacy of our vaccine using the wellcharacterized RABV challenge model. All of the FiloRab1 PBV–,
FiloRab1 –80°C–, and RabAvert control–vaccinated animals
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